On March 13, 2024, Merck Sharp & Dohme, LLC ("Merck") filed four additional IPRs challenging The Johns Hopkins University ("JHU") patents covering methods of treatment using pembrolizumab, which Merck sells under the trade name Keytruda®. These follow four IPRs filed by Merck on March 4, 2024 that we previously reported (see Merck Files Four IPRs Challenging The Johns Hopkins University Pembrolizumab Patents, March 12, 2024). The new IPRs are IPR2024-00647 challenging U.S. Patent No. 11,649,287; IPR2024-00648 challenging U.S. Patent No. 11,643,462; IPR2024-00649 challenging U.S. Patent No. 11,629,187; and IPR2024-00650 challenging U.S. Patent No. 11,634,491 as being anticipated by and obvious over the prior art.
Similar to the March 4th IPRs, the new IPRs also challenge patents that are involved in an ongoing lawsuit filed by Merck against JHU in November 2022 (1:22-cv-03059 (D. Md.)). Merck has now filed IPRs on all of the patents involved in that litigation. The litigation remains ongoing and the IPRs are awaiting Institution Decisions.
Keytruda® was the world's top selling drug in 2023, with $25 billion in world-wide sales.
We continue to monitor the Keytruda® IPRs and litigation and will provide updates as they become available. For more information about these and other biosimilar and biologic drug patent disputes, visit BiologicsHQ.
For more information on this and other biosimilars, visit BiologicsHQ.
The author would like to thank April Breyer Menon for her contributions to this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
